Cordyceps Sunshine Biotech Holdings Co., Ltd. financials

RAJAF CIK 0001885680

Source: EDGAR filings · Built 2026-06-19T03:02:03Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Free Cash Flow -37.23K 40.24K -321.85K -465.36K -1.24M
EBITDA -5.88K 223.35K 284.59K -390.63K 29.85K 35.37K
Working Capital -4.19M -4.39M -2.64M -2.02M -1.79M -1.46M
Net Debt 475.21K 510.49K 604.42K 906.27K 1.70M 1.52M
Gross Margin 61.09% 72.32% 86.84% 74.21% -20.04% 69.83%
Operating Margin -11.33% -14.67% 25.82% -778.78% -13.58% 6.48%
Net Margin -12.43% -18.05% 85.17% -1350.92% -55.84% -10.00%
Return on Equity (ROE) 28.96% 60.25% -495.14% 75.69% 178.02% 105.18%
Return on Assets (ROA) -3.32% -4.89% 22.42% -34.21% -15.05% -0.48%
Current Ratio 0.19× 0.12× 0.11× 0.20× 0.39× 0.39×
Debt-to-Equity -0.90× -1.46× -4.13× -0.96× -6.52× -118.90×
Effective Tax Rate -18.27% 11.28% -0.19% -0.29%
Cash Conversion Ratio 0.23× -1.38× 0.48× 0.45× 0.74× 9.69×
Accruals Ratio -0.03× -0.12× 0.12× -0.19× -0.04× 0.04×
CapEx Coverage 0.89× 1.13× -676.59× -3.65× -0.12×
Free Cash Flow Per Share $-0.00 $0.00 $-0.00 $-0.00 $-0.01

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Revenues 1.25M 1.25M 882.53K 53.30K 879.32K 134.72K
Cost of Revenue 484.61K 347.00K 116.15K 13.75K 1.06M 40.65K
Gross Profit 760.74K 906.48K 766.39K 39.56K -176.21K 94.07K
Research and Development Expense 118.44K 25.05K
Operating Expenses 901.87K 1.09M 538.55K 454.68K 119.39K 85.34K
Operating Income (Loss) -141.13K -183.91K 227.83K -415.12K -119.39K 8.73K
Income Tax Expense (Benefit) 34.96K 21.53K 792 351 1.94K
Net Income (Loss) Attributable to Parent -154.82K -226.26K 751.61K -720.09K -491.01K -13.48K
Earnings Per Share, Basic $0.00 $0.00 $0.01 $-0.01 $-4.91 $0.00
Weighted Average Number of Shares Outstanding, Basic 111.12M 111.12M 111.12M 104.42M 100.00M 100.00M
Earnings Per Share, Diluted $0.00 $0.00 $0.01 $-0.01 $-4.91 $0.00
Weighted Average Number of Shares Outstanding, Diluted 111.12M 111.12M 111.12M 104.42M 100.00M 100.00M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Cash and Cash Equivalents, at Carrying Value 3.20K 37.28K 23.10K 6.63K 99.68K 294
Assets, Current 997.74K 601.60K 327.18K 501.55K 1.13M 949.01K
Assets 4.66M 4.62M 3.35M 2.10M 3.26M 2.83M
Liabilities, Current 5.19M 4.99M 2.97M 2.52M 2.92M 2.41M
Long-term Debt, Excluding Current Maturities 431.08K 414.00K
Liabilities 5.19M 5.00M 3.50M 3.06M 3.54M 2.84M
Stockholders' Equity Attributable to Parent -534.55K -375.54K -151.80K -951.33K -275.81K -12.81K
Common Stock, Shares, Outstanding 111.12M 111.12M 111.12M 111.12M 111.12M 111.12M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2022FY 2022
Net Cash Provided by (Used in) Operating Activities -35.84K 312.01K 359.72K -321.38K -365.36K -130.55K
Payments to Acquire Property, Plant, and Equipment 349.24K 319.49K 475 100.00K 1.11M
Net Cash Provided by (Used in) Investing Activities -305.64K -319.82K -475 -110.81K -1.50M
Net Cash Provided by (Used in) Financing Activities -32.21K 245.79K 574.50K 1.63M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (RAJAF CIK 0001885680), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

PRTH

Priority Technology Holdings, Inc.

AMLX

Amylyx Pharmaceuticals, Inc.

GMBL

ESPORTS ENTERTAINMENT GROUP, INC.